Jennison Associates LLC Denali Therapeutics Inc. Transaction History

Jennison Associates LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$29.0 - $47.27 $6.5 Million - $10.6 Million	-224,184 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$42.59 - $55.02 $180,496 - $233,174	-4,238 Reduced 1.86%	224,184 $10 Million
Q3 2021 Nov 09, 2021	SELL	$48.48 - $78.23 $7.08 Million - $11.4 Million	-146,090 Reduced 39.01%	228,422 $11.5 Million
Q1 2021 May 11, 2021	SELL	$53.8 - $81.53 $161,400 - $244,590	-3,000 Reduced 0.79%	374,512 $21.4 Million
Q4 2020 Feb 05, 2021	SELL	$36.89 - $93.56 $229,271 - $581,475	-6,215 Reduced 1.62%	377,512 $31.6 Million
Q3 2020 Nov 04, 2020	SELL	$23.13 - $38.84 $1.32 Million - $2.21 Million	-56,914 Reduced 12.92%	383,727 $13.7 Million
Q2 2020 Aug 06, 2020	BUY	$16.01 - $28.82 $28,209 - $50,780	1,762 Added 0.4%	440,641 $10.7 Million
Q1 2020 May 06, 2020	BUY	$14.2 - $27.98 $6.23 Million - $12.3 Million	438,879 New	438,879 $7.69 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.